Overview of Nimofar Plus

Quick Facts

Property	Description
Active ingredient	Citicoline and Nimodipine
Form	Film-coated tablet (Oral administration)
Pharmacological class	Combination Nootropic and Dihydropyridine Calcium Channel Antagonist
General Purpose	Support neurological function and optimize cerebral blood flow
Origin	Semi-synthetic (Citicoline) and Synthetic (Nimodipine)

What Type of Medicine is Nimofar Plus?

Nimofar Plus is a fixed-dose combination product containing two active substances designed to support the central nervous system. This dual categorization places it within the Neuroprotective Agent class, which is intended to protect nerve cells, and the Dihydropyridine Calcium Channel Blocker class, which primarily acts on vascular smooth muscle. This integrated classification reflects an advanced therapeutic approach, aiming to address both the vascular environment and the cellular integrity of compromised brain function simultaneously. For instance, the combination has been clinically recognized for providing an additive neuroprotective effect in pharmacological models of cerebral ischemia.

Core Composition and Pharmaceutical Form

The medicine's composition features the internationally recognized active ingredients Nimodipine and Citicoline (CDP-choline). Nimodipine is a highly lipophilic synthetic compound belonging to the dihydropyridine family. Citicoline, conversely, is a vital endogenous intermediate obtained in the biosynthetic pathway of structural phospholipids in cell membranes, and is often classified as a nootropic agent. This dual combination is commercially available under various brand names globally, signifying its specific application across diverse regional markets. Nimofar Plus is supplied for oral administration, typically formulated as a film-coated tablet or similar solid pharmaceutical preparation.

General Purpose: Dual Action Support for the Brain

The general purpose of Nimofar Plus is to provide comprehensive support for neurological function by employing a targeted dual action mechanism. This approach utilizes the Nimodipine component to selectively influence cerebral arteries, promoting vessel relaxation to ensure sufficient cerebral blood flow. Concurrently, the Citicoline component provides necessary building blocks, supporting the membrane stabilization and structural integrity of the nerve cells. This integrated strategy is clinically aimed at optimizing the vascular supply and enhancing cellular survival, a rationale often employed for conditions related to focal cerebral ischemia.

Regulatory References

Nimodipine FDA Label (DailyMed/NIH)

What side effects are possible with Nimofar Plus?

Possible Side Effects and Safety Information

The officially documented adverse effects for Nimofar Plus, a combination of Citicoline and Nimodipine, are classified according to frequency and the body systems affected, following standards set by regulatory authorities such as the EMA and FDA.

Documented Adverse Reactions

The adverse effects reported in official labeling are primarily linked to the vascular activity of the Nimodipine component.

Classification	Examples of Adverse Reactions
Common	Hypotension (decreased blood pressure), Headache, Nausea, Diarrhea, and Bradycardia (slow heart rate).
Uncommon	Allergic reactions and Thrombocytopenia (decreased platelet count).

Serious Safety Considerations

Certain reactions are documented as clinically significant safety concerns in regulatory sources. Severe Hypotension is a serious adverse reaction noted in the label, reflecting the drug's effect on blood pressure. The official labeling also highlights Thrombocytopenia as an uncommon but serious adverse event.

Safety Constraints and Special Populations

Safety constraints define the limitations of the medicine's use. It is contraindicated in individuals with severe hepatic impairment due to the risk of drastically increased Nimodipine plasma concentrations, which heightens the risk of side effects. Furthermore, official documents note that effects such as headache and flushing may be more frequent at the start of treatment or following an increase in dose. Caution is also advised for patients with severely impaired renal function and for older adults, who may have an increased susceptibility to blood pressure changes.

Overdose and Emergency Response

Overdose and When to Seek Help

The section “Overdose and when to seek help” is guided by the official regulatory profile of the active ingredients, primarily focusing on the Nimodipine component. The second component, Citicoline, exhibits a very low toxicity profile and is generally not associated with severe overdose complications.

Officially documented manifestations of over-exposure include profound marked systemic hypotension (extremely low blood pressure) resulting from excessive peripheral vasodilation. Other severe cardiovascular signs can involve profound changes in heart rate, such as bradycardia (slowed heart rate) or tachycardia (rapid heart rate). Gastrointestinal disturbances such as nausea, vomiting, and diarrhea may also be present. Severe cases carry the risk of life-threatening outcomes, including shock and cardiovascular collapse.

Immediate Emergency Action is Mandatory

If an overdose is suspected, or if a victim has collapsed, has trouble breathing, or is exhibiting these severe symptoms, the regulatory requirement is to seek medical help right away and contact emergency services immediately.

There is no specific antidote known. Management is strictly symptomatic and supportive, and is handled in a monitored hospital setting. Treatment involves active cardiovascular support, including the use of pressor agents to counteract severe hypotension. Specific procedural measures for calcium channel blocker toxicity may be initiated by medical professionals.

Therapeutic Uses of Nimofar Plus

What Nimofar Plus Treats: Main Uses and Benefits

Nimofar Plus is a combination therapy generally used to provide supportive care for conditions where compromised cerebral blood flow impacts neurological function. The treatment is commonly applied in clinical scenarios that require assistance in managing symptoms related to vascular health in the brain's circulation.

The Nimodipine component is applied to help manage neurological deficits and provides supportive therapeutic benefit in adult patients with subarachnoid hemorrhage (SAH).

The medication is considered relevant for long-term supportive management of chronic cerebral ischemia and cerebral small vessel disease. It contributes to easing the overall symptom load associated with these conditions characterized by periods of heightened symptoms. The treatment may assist with memory, attention, and functional stability in patients with vascular cognitive impairment, supporting them during episodes of heightened discomfort.

“The supportive therapeutic benefit may assist with managing cognitive symptoms that interfere with daily comfort.”

Quick Fact: Relief for Cognitive Strain
Primary Symptom Area	Forgetfulness and poor concentration related to vascular factors.
Typical Context	Chronic and progressive vascular cognitive decline in older adults.
Patient Benefit	May assist with maintaining functional stability in day-to-day mental functioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nimofar Plus?

The population eligibility for Nimofar Plus is defined by the official regulations governing its two active components, Nimodipine and Citicoline. Use is generally established in adult patients for its core approved purposes.

Contraindicated Populations (Must Not Use)	Conditional/Restricted Use
Hypersensitivity to Nimodipine, Citicoline, or any excipient.	Hepatic Impairment: Requires mandatory dose reduction due to significantly increased Nimodipine exposure.
Hypertonia of the parasympathetic nervous system (Citicoline component).	Older Adults: Requires increased monitoring due to higher drug concentration (approx. 2-fold higher Cmax for Nimodipine).
Concomitant use with strong CYP3A4 inhibitors (e.g., certain antibiotics, antifungals).	Pediatric Patients: Use is limited; safety and efficacy are generally not established under 18 years of age.

Use during pregnancy and breastfeeding is restricted and generally not recommended unless the potential benefit is determined to outweigh the risk, as stated in the official prescribing information. Patients with pre-existing hypotension must be monitored closely.

What should I know about interactions with other medicines?

The regulatory interaction profile for Nimofar Plus, a combination of Nimodipine and Citicoline, is based on the metabolic and pharmacodynamic properties of each active component as documented in official government sources.

Pharmacokinetic Interactions

The Nimodipine component is metabolized primarily by the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors, such as certain azole antimycotics and HIV protease inhibitors, is generally avoided because it significantly increases Nimodipine exposure and the risk of adverse effects. Conversely, strong CYP3A4 inducers, including Rifampin and antiepileptics like Phenytoin and Carbamazepine, are formally contraindicated in some regions, as they accelerate clearance and reduce efficacy.

Pharmacodynamic and Substance Interactions

The Citicoline component has a documented pharmacodynamic interaction, leading to an enhancement of effects when combined with L-dopa/Levodopa. Co-administration with Meclofenoxate (Clophenoxate) is officially prohibited. Substances that inhibit CYP3A4, such as Grapefruit Juice, must also be avoided.

Timing and Population Restrictions

A mandatory timing rule exists: the medicine must be administered one hour before a meal or two hours after a meal to prevent a significant reduction in Nimodipine's bioavailability. For patients with hepatic impairment, metabolism is decreased, resulting in increased plasma concentrations and requiring a population-specific exposure adjustment.

Mechanism of Action

Nimofar Plus is a fixed-dose combination containing nimesulide and paracetamol (acetaminophen), each component modulating distinct physiological pathways.

Nimesulide functions as an inhibitor primarily targeting the enzyme cyclooxygenase-2 (COX-2). This selective inhibition impedes the conversion of arachidonic acid into prostaglandins, lipid compounds that act as local cellular mediators. The consequent reduction in prostaglandin synthesis affects peripheral and central signaling cascades. Furthermore, nimesulide exhibits non-COX related interactions, including inhibition of matrix metalloproteinases (MMPs) and reduction of oxidant release from activated neutrophils.

Paracetamol's central mechanism involves a poorly understood interaction within the central nervous system. It is believed to operate as an inhibitor of central COX pathways, reducing central prostaglandin concentration. Additionally, paracetamol is metabolized to AM404, which may act on the transient receptor potential vanilloid 1 (TRPV1) receptor and cannabinoid 1 (CB1) receptor, altering intracellular calcium signaling and neurotransmitter release. The combined actions of both components modulate the synthesis and activity of cellular mediators, impacting system-level thermoregulatory and afferent neural signaling pathways.

Dosage and Administration Information

How Nimofar Plus is Used

Nimofar Plus is an oral fixed-dose combination medication supplied as a film-coated tablet, which defines the route of administration. The usage of this medicine is structured around two principal patterns based on the established characteristics of its components.

Standard Dosing Regimens and Administration Context

Instruction	Detail
Route of administration	Oral administration, swallowing the film-coated tablet whole with water.
Standard Dose Range	The nimodipine component is dosed at 60 mg per administration for the acute regimen; the citicoline component is commonly included in ranges up to 1000 mg daily.
Administration Timing	Intake is generally permitted with or without food.

Use Frequency and Duration Protocols

For conditions requiring acute vascular support, the regimen is highly structured: a dose is typically administered every four hours (q4h). This high-frequency pattern is maintained for a defined period, such as 21 consecutive days. This acute protocol usually requires initiation under specialist supervision.

Conversely, for long-term supportive care related to chronic neurological support, the medicine follows a less frequent schedule, often administered once or twice daily in an outpatient setting.

Population-Specific Instructions

Dose adjustments may be necessary for patients with hepatic impairment. Clinical considerations indicate that a reduced dose or an extended dosing interval is required to account for changes in drug clearance. If a scheduled dose is missed, the standard practice is not to double the next dose; the regular schedule is resumed after taking the missed dose, unless the next dose is imminent.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nimofar Plus

This section provides an overview of the research and clinical trial data available for the active components of Nimofar Plus—Citicoline and Nimodipine—focusing on the research context and the nature of the reported findings. This information describes what has been studied by researchers and should not be used for therapeutic recommendations.

Evidence for Use in Vascular Cognitive Support

Research has studied the components of Nimofar Plus in the context of conditions where compromised blood flow in the brain, such as chronic cerebral ischemia, may lead to neurological symptoms like memory and attention changes. Studies have primarily involved Randomized Controlled Trials (RCTs) focusing on the Citicoline component alone, alongside some smaller, exploratory studies for the combination. This research explored whether specific cognitive functions and patient-reported overall daily functioning changed during the study period.

The studies focused on populations of older adults with mild-to-moderate memory deficits, patients with post-stroke cognitive impairment (PSCI), or those diagnosed with cerebral small vessel disease. Studies related to the single-agent Citicoline component reported measurements of changes concerning attention and other specific cognitive domains. However, findings varied when assessing the overall, global changes in cognitive function across different trials.

The evidence for the use of the specific combination of Nimodipine and Citicoline for this intended long-term setting remains limited and evidence quality varies across studies. Comparative evidence showing how this combination performs against other standard maintenance therapies is lacking.

Evidence for Acute Neurological Support (Subarachnoid Hemorrhage)

The evidence supporting the Nimodipine component was evaluated in a different, acute-care context: for use in patients with neurological deficits that followed vasospasm after a subarachnoid hemorrhage (SAH). The core evidence here is derived from large-scale, controlled clinical trials. These studies monitored outcomes such as the occurrence of delayed cerebral ischemia and outcomes reflecting daily functioning or activity level.

The Nimodipine component was evaluated against placebo in studies of overall outcomes when administered immediately after the hemorrhage. The conclusions drawn from the evidence in this indication are primarily related to the established regulatory use of Nimodipine as a single agent. While the Nimodipine component is a highly studied component in this acute, life-threatening situation, research specifically combining both agents for this acute indication is not fully established.

Research Gaps and What Remains Uncertain

Long-term effects are not fully established for this combination. Research so far indicates that the follow-up durations used often provide insight into short-term changes but leave uncertainty about the durability of the observed changes. The results apply only to the populations studied, meaning the findings describe group patterns, not personal outcomes. Evidence quality varies across studies, and there is a recognized lack of large, long-term studies specifically evaluating the fixed-dose combination for its role in chronic neurological conditions.

Frequently Asked Questions (FAQ)

Common questions about Nimofar Plus (FAQ)

Q: How long does it usually take for Nimofar Plus to start working?

According to official product information, the nimodipine component of the medicine is quickly absorbed into the body. It generally reaches its highest concentration in the bloodstream within about one hour after the tablet is taken by mouth.

Q: How long do the pain-relieving effects from one dose of Nimofar Plus be expected to last?

The nimodipine component has a short elimination half-life, which is the time it takes for half of the drug to be removed from the body. This is reported to be about one to two hours. This short half-life is consistent with the need for frequent administration in certain structured regimens.

Q: Is Nimofar Plus intended for short-term relief or long-term chronic use?

Official guidelines describe different use protocols for this medicine. The structured acute regimen for one of the core indications is for a defined period, often 21 consecutive days. The medicine is also administered on a less frequent schedule, such as once or twice daily, for certain long-term supportive care.

Q: Is it necessary to avoid alcohol while taking Nimofar Plus?

Official product labeling indicates that the nimodipine component may have an additive effect in lowering blood pressure when combined with alcohol. Additionally, some specific liquid formulations of nimodipine contain ethanol, or alcohol, which may be harmful to certain patient populations.

Q: Is it necessary to take Nimofar Plus with food to prevent an upset stomach?

To ensure the nimodipine component is properly absorbed, regulatory instructions describe the medicine as being administered one hour before a meal or two hours after a meal. Taking it at other times may significantly reduce how much of the medicine the body receives.

Q: Is it true that Nimofar Plus can cause drowsiness or sleepiness?

The medicine may cause effects such as dizziness or faintness in some patients, particularly when starting treatment or when the dose is increased. Official patient guidance states that caution should be exercised before driving or using machines if this occurs.

Q: What is the general guidance on what to do if a dose of Nimofar Plus is missed?

Official instructions state that if a scheduled dose is missed, doubling the next dose is advised against. Information on managing a missed dose is provided by the prescribing physician, and this should be consulted for specific directions.

Q: Is Nimofar Plus typically prescribed for older adults?

While use in older adults is generally permitted, this population requires increased monitoring during treatment. This is due to the potential for higher drug concentrations in the body and an increased susceptibility to changes in blood pressure.

Q: Can Nimofar Plus affect the results of certain medical lab tests?

According to the official product labeling, the nimodipine component is reported to have no known interactions with standard laboratory tests.

Q: Is there a long-term risk associated with using Nimofar Plus regularly?

Research summarized in official documentation indicates that the durability of observed changes and long-term effects are not fully established for this specific combination. Studies often provide insights into short-term changes but leave uncertainty about the long-term safety profile.

Q: What warning signs should someone look for that may indicate a serious side effect?

Official product labeling documents Severe Hypotension (severe low blood pressure) and Thrombocytopenia (a decreased platelet count) as clinically significant safety concerns. Signs of severe low blood pressure can include feeling dizzy, lightheaded, or fainting.

Q: Can Nimofar Plus be taken alongside common vitamins or mineral supplements?

Regulatory information suggests that multivitamins with minerals may potentially reduce the effects of the nimodipine component in the body. The co-administration of the two is described in regulatory information as potentially necessitating careful monitoring.

Q: Does Nimofar Plus interact with prescription medications for depression or anxiety?

The nimodipine component is processed in the body by the CYP3A4 enzyme system. The official label discusses the need for caution regarding medicines that inhibit or induce this enzyme, which includes certain medications for epilepsy or other conditions, due to the risk of altering drug levels.

Q: Are there any specific foods or beverages that should be avoided when taking Nimofar Plus?

Official documents state that Grapefruit and grapefruit juice are prohibited as they can significantly increase the blood levels and potential effects of the nimodipine component.

Q: Are there different strengths or formulations of Nimofar Plus available?

The nimodipine component of the combination medicine is available in various strengths and formulations. These can include a liquid oral solution or other solid preparations like capsules or tablets.

Q: How should Nimofar Plus be stored at home?

Regulatory storage requirements describe the medicine as being maintained at Controlled Room Temperature (20° to 25°C). The product must be kept protected from light and moisture, and freezing is prohibited.

Q: What is the process for safely disposing of unused Nimofar Plus tablets?

Official documents state that the patient should consult a healthcare professional or a pharmacist for specific guidance on how to safely dispose of any unused or expired tablets. This ensures the product is discarded according to local regulations.

Q: Does Nimofar Plus affect the ability to drive or operate machinery?

Official patient guidance states that caution should be exercised, as the medicine may cause effects such as dizziness or faintness in some patients. This is due to the potential to impair the ability to drive or operate machinery.

Q: Is Nimofar Plus known to cause problems with blood clotting?

Official regulatory labeling documents Thrombocytopenia (a decreased platelet count) as an uncommon but serious adverse reaction. Platelets are a type of blood cell involved in clotting.

Q: Can Nimofar Plus affect a patient's appetite?

The medicine is associated with gastrointestinal effects, including nausea and diarrhea. Official patient guidance has also listed loss of appetite as a possible side effect in some patients.

Q: Is Nimofar Plus approved for treating symptoms other than pain and inflammation?

The primary general purpose of the medicine is to provide comprehensive support for neurological function and to optimize cerebral blood flow. This differs from the use of typical pain and inflammation relievers.

How should Nimofar Plus be stored and disposed of?

How to Store and Dispose of Nimofar Plus

The storage and disposal instructions for Nimofar Plus are officially regulated to maintain the product's quality and ensure safety. The medicine must be stored at Controlled Room Temperature, specifically between 20° to 25°C (68° to 77°F), with excursions up to 30°C permitted.

Mandatory Storage Conditions

Protection: The medicine must be actively protected from light and moisture, and it is strictly prohibited to freeze the product.
Container: Store the product in its manufacturer's original package and ensure the container remains closed.
Safety: The medication must be kept out of the reach of children.

Disposal Instructions

To dispose of unused or expired Nimofar Plus, individuals are directed to ask a healthcare professional for specific guidance. This ensures that the product is discarded safely and according to local regulations, preventing inappropriate disposal.

Nimofar Plus